OTSKY: Otsuka Holdings insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
10 institutions reported holding $102.66M of Otsuka Holdings on Form 13F (10 the quarter before). 1 opened a new position and 1 sold out. Shares held by institutions: -2%.
| Largest holders | Shares | Value |
|---|---|---|
| Aristotle Capital Management, LLC | 2,944,596 | $97.93M |
| Boston Common Asset Management, LLC | 82,860 | $2.77M |
| RHUMBLINE ADVISERS | 45,793 | $1.53M |
| GAMMA Investing LLC | 9,262 | $310K |
| Westside Investment Management, Inc. | 1,418 | $47K |
| First Command Advisory Services, Inc. | 943 | $32K |
| Salomon & Ludwin, LLC | 723 | $24K |
| PNC Financial Services Group, Inc. | 131 | $4K |
| IMA Advisory Services, Inc. | 79 | $3K |
| HANTZ FINANCIAL SERVICES, INC. | 71 | $2K |
Clinical trial readouts
10 Phase 2 or 3 trials by Otsuka Holdings with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-10-20 (est.) | SEP-363856 | Schizophrenia | Phase 3 | 538 | Enrollment complete | NCT06894212 |
| 2026-12 (est.) | OPA-15406 | Atopic Dermatitis (AD) | Phase 3 | 156 | Not yet recruiting | NCT07173478 |
| 2027-02 (est.) | OPA-15406 | Atopic Dermatitis (AD) | Phase 3 | 198 | Not yet recruiting | NCT07184645 |
| 2027-03-13 (est.) | Sibeprenlimab | Sjogren Disease | Phase 2 | 83 | Enrollment complete | NCT06928142 |
| 2027-05-27 (est.) | Centanafadine XR | Attention-deficit/Hyperactivity Disorder | Phase 3 | 80 | Recruiting | NCT07759154 |
| 2027-06-30 (est.) | OPF-310 | Diabetes Mellitus, Type 1 | Phase 1/2 | 13 | Recruiting | NCT06575426 |
| 2027-08 (est.) | EB-1020 (Centanafadine) low dose | Attention-Deficit Hyperactivity Disorder(ADHD) | Phase 2/3 | 315 | Recruiting | NCT07086313 |
| 2027-08 (est.) | EB-1020 (Centanafadine) low dose | Attention-Deficit Hyperactivity Disorder(ADHD) | Phase 3 | 180 | Recruiting | NCT07087327 |
| 2027-09 (est.) | OPC-34712FUM/ Brexpiprazole fumarate | Acute Schizophrenia | Phase 3 | 450 | Recruiting | NCT05325645 |
| 2027-11-01 (est.) | JNT-517 | Phenylketonuria (PKU) | Phase 3 | 240 | Recruiting | NCT06628128 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.